TL;DR
- 1.The standard 2.5mg twice-weekly loading protocol makes pharmacological sense but was never tested in a randomized trial. It comes from research vendor guidance, not clinical dosing studies.
- 2.Loading phase (4-6 weeks at higher dose) builds tissue saturation. Maintenance (1.5-2mg weekly) sustains it. Most users skip maintenance and wonder why effects fade after 6 weeks.
- 3.TB-500 distributes systemically. You do not need to inject near the injury. The abdomen works as well as the shoulder for a rotator cuff tear.
- 4.The strongest controlled human data for thymosin beta-4 is in corneal repair, not tendons. The 2025 scoping review calls musculoskeletal evidence 'comparatively sparse.'
- 5.WADA banned TB-500 in January 2026. The FDA removed it from the do-not-compound list in April 2026 and scheduled a formal authorization review for July 23-24, 2026.
The 2.5mg twice-weekly loading protocol that fills every TB-500 forum has never been validated in a randomized clinical trial. The only published human pharmacokinetics study (a 2021 Phase 1 trial in the Journal of Cellular and Molecular Medicine) confirmed dose-proportional clearance up to 25 mcg/kg without serious adverse events, but was designed to test safety and pharmacokinetics, not to optimize protocol structure. The loading schedule you have probably read a dozen times derives from research vendor guidance, not peer-reviewed dosing data.
That does not make it wrong. It makes it empirically derived. There is a meaningful difference. This guide explains the pharmacological rationale behind loading, covers maintenance dosing by body weight, maps three injury-specific protocols to the actual evidence, and answers the injection-site question that competitor articles leave unresolved.
Complete corneal healing at week 4 in the SEER-1 Phase 3 trial testing 0.1% thymosin beta-4 eye drops (RGN-259). The placebo group achieved 12.5%. This is the strongest controlled human outcome data for thymosin beta-4's therapeutic mechanism, and it involves tissue almost nobody using TB-500 is targeting.
TB-500 is a synthetic fragment of thymosin beta-4, a protein that naturally regulates actin polymerization inside cells. When tissue is injured, free actin released from damaged cells rises sharply. Thymosin beta-4 binds this free actin, preventing it from forming the disordered scaffolds that lead to excess scar tissue. Simultaneously, it promotes the migration of progenitor cells, upregulates blood vessel formation, and reduces inflammation through prostaglandin E2 suppression.
The practical result: faster clearance of inflammatory debris, new vascular growth into the healing zone, and a reduction in fibrotic remodeling. You get quicker tissue maturation with less scar quality compromise. The 2025 scoping review in Applied Sciences, which mapped all TB-500 and thymosin beta-4 tissue-repair research through March 2026, confirmed this mechanism across multiple tissue types, while noting that musculoskeletal evidence in humans remains largely absent.
Think of a construction site after an earthquake. The debris (free actin) is everywhere. TB-500 is the site manager who coordinates cleanup, calls in new workers (progenitor cells), and makes sure rebuilding happens with proper materials instead of whatever is lying around. Without the site manager, cleanup happens eventually. With the site manager, it happens faster and the rebuilt structure is stronger.
What does the loading phase actually do, and why does it take 4 to 6 weeks?
TB-500 is not a receptor agonist that produces an immediate pharmacological response. It works by saturating tissue with thymosin beta-4, which then modulates the local cellular environment over time. Loading builds tissue levels faster than a maintenance schedule alone would achieve.
The 2021 human Phase 1 study found no drug accumulation on repeat dosing at standard intervals, which is pharmacokinetically favorable. It means you can dose repeatedly without exponential buildup, and that systemic clearance is predictable. What the study did not test: whether twice-weekly dosing builds meaningfully higher tissue concentrations than once-weekly dosing during a loading window. That question remains answered only by preclinical data and community experience.
The four-to-six-week loading window reflects collagen remodeling biology, not a dose-escalation study. Tendon and ligament collagen completes one full remodeling cycle in roughly four to six weeks. Running TB-500 for less than this window may saturate systemic tissue but may not complete a collagen remodeling cycle in the target tissue. Running longer than six weeks at loading dose adds cost without a clear benefit signal for most injury types.
| Phase | Standard dose | Frequency | Duration | Purpose |
|---|---|---|---|---|
| Loading | 2.0-2.5mg | Twice weekly | 4-6 weeks | Build tissue saturation |
| Maintenance | 1.5-2.0mg | Once weekly | Ongoing or 4-8 more weeks | Sustain tissue levels |
| Acute injury | 2.5-3.0mg | Twice weekly | Until resolved or 4 weeks | Accelerate acute repair |
| Preventive or performance | 1.0-2.0mg | Once weekly | Off-season or ongoing | Connective tissue resilience |
The maintenance phase is the most skipped step in TB-500 protocols. Most users run 4 to 6 weeks of loading, notice improvement, and stop entirely. Effects fade within four to eight weeks post-cycle because tissue levels drop below the threshold needed to sustain collagen remodeling activity. The loading phase gets tissue to a functional state. Maintenance keeps it there.
How to calculate your maintenance dose by body weight
Flat-dose protocols (2mg regardless of body size) dominate most guides. This is reasonable for most users, since the Phase 1 human PK study found dose-proportional clearance up to 25 mcg/kg, and 2mg falls within that range for anyone between 60 and 100kg. If you are outside that weight range, or if you have not responded to the standard protocol, a weight-adjusted dose gives you a more precise starting point.
| Body weight | Loading dose (25 mcg/kg) | Maintenance dose (15 mcg/kg) |
|---|---|---|
| 60 kg / 132 lb | 1.5mg | 0.9mg |
| 70 kg / 154 lb | 1.75mg | 1.05mg |
| 80 kg / 176 lb | 2.0mg | 1.2mg |
| 90 kg / 198 lb | 2.25mg | 1.35mg |
| 100 kg / 220 lb | 2.5mg | 1.5mg |
| 110 kg / 242 lb | 2.75mg | 1.65mg |
The 25 mcg/kg loading reference aligns with the upper dose range in the 2021 Phase 1 clinical trial. The 15 mcg/kg maintenance figure derives from preclinical tissue-saturation models and community experience, not from a controlled dosing study. Use it as a starting point, not a precision calculation.
Your genetics affect how long you stay in the loading phase, not just the starting dose. Carriers of certain COL5A1 polymorphisms, which are associated with longer injury recovery in endurance athletes, may need six weeks of loading to achieve the tissue-level effect that typical responders see at four weeks. If you have checked your collagen gene variants, use that data to calibrate phase duration before defaulting to the four-week standard.
Which TB-500 protocol actually fits your injury type?
Every guide gives the same 2.5mg twice-weekly chart regardless of whether you have a partial Achilles tear, post-surgical recovery, or chronic tendinopathy that has not healed in 18 months. These are not the same injury. Here are three injury-specific protocols mapped to what the evidence actually supports.
Acute muscle tear or strain
Start at 2.5 to 3.0mg twice weekly as early as possible after injury. The first 72 hours is the highest-leverage window for reducing inflammatory debris and promoting progenitor cell migration into the injury zone. Run at this dose for 4 weeks, then reassess. Most acute muscle injuries show measurable functional recovery between weeks 3 and 4. Transition to 2mg once weekly for 4 more weeks as maintenance. Total minimum cycle: 8 weeks. For a direct comparison of TB-500 vs BPC-157 in muscle injury, see the head-to-head evidence review.
Chronic tendinopathy
Chronic tendinopathy involves degenerative changes, not acute inflammation. The mechanism is different: less about clearing inflammatory debris and more about promoting new collagen synthesis and vascular ingrowth into the avascular tendon core. Start at 2mg twice weekly. Run for 6 weeks, not 4, because collagen maturation in degenerated tissue is slower than in acute injury. Transition to 2mg once weekly for an 8-week maintenance phase. Expect the response window to be weeks 6 to 10, not weeks 3 to 4. No response by week 8 suggests either a genetic response-time variant or that the injury requires BPC-157 stacking for the local nitric oxide signal it provides.
Post-surgical recovery
Wait until primary wound closure is confirmed before starting, typically 2 weeks after surgery. Then begin at 2mg twice weekly. The goal is accelerating secondary remodeling, not the initial healing phase where surgical repair must complete without disruption. Run the full 6-week loading phase. Post-surgical soft tissue remodeling continues for 12 to 18 months. Maintenance dosing at 1 to 2mg weekly during this active remodeling window is where the long-term benefit accumulates. Follow the injection hygiene guide carefully before starting any injectable protocol post-surgery.
For joint and cartilage repair, the evidence is thinner still. The 2025 Applied Sciences scoping review found that tendon, ligament, and cartilage evidence is "comparatively sparse" with no completed human musculoskeletal trials. If you are targeting joint cartilage, understanding the pharmacokinetics of both TB-500 and BPC-157 is essential before choosing your protocol. The half-life and tissue clearance guide covers the PK data in depth.
Does TB-500 injection site actually matter? The answer most articles avoid
Here is the finding that most guides leave unresolved: TB-500 distributes systemically. Where you inject does not meaningfully change which tissue receives it.
This is different from BPC-157. BPC-157 is often injected near the target tissue because it operates partly through local concentration gradients at the injury site. TB-500 works differently. After subcutaneous injection, it enters systemic circulation and distributes broadly across tissues. Injecting into the abdomen, thigh, or glute produces the same systemic tissue exposure as injecting near a rotator cuff tear. The 2021 Phase 1 study confirmed predictable systemic distribution after subcutaneous administration in healthy volunteers across all dose cohorts.
Recombinant human thymosin beta-4 showed dose-proportional pharmacokinetics following both intravenous and subcutaneous administration, with predictable systemic distribution and no dose accumulation on repeat dosing across all cohorts.
Wang et al., Journal of Cellular and Molecular Medicine, 2021
The practical implication: rotate injection sites for skin comfort and tissue health, not for efficacy. The abdomen is the most common choice because it is accessible and subcutaneous tissue depth is consistent. If you are also running BPC-157 for the same injury, inject BPC-157 locally and TB-500 in the abdomen. Each peptide is handled according to its mechanism, not the same generic protocol.
| Peptide | Injection site strategy | Rationale |
|---|---|---|
| TB-500 | Abdomen (rotate sites) | Systemic distribution. Location does not affect target tissue delivery. |
| BPC-157 | Near injury site preferred | Local concentration gradient amplifies effect at target tissue. |
| Combined protocol | TB-500: abdomen. BPC-157: near injury. | Each peptide handled by its optimal delivery mechanism. |
Is TB-500 legal to source in the US in 2026?
The regulatory status of TB-500 shifted twice in the past 12 months. In October 2023, the FDA placed thymosin beta-4 on its 503A Category 2 list, prohibiting US compounding pharmacies from producing it. That remained in effect through early 2026. In April 2026, the FDA removed TB-500 from Category 2 and scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 23-24, 2026.
The pre-meeting FDA briefing documents propose that TB-500 not be added to the 503A Bulks List, which would keep it unavailable through licensed US compounding pharmacies. A final determination depends on the PCAC vote and subsequent FDA ruling. As of publication, that meeting is days away and its outcome will determine US compounding access for the near term.
TB-500 is not a DEA Schedule I or II controlled substance. The legal question involves compounding and biologic classification (the FDA reclassified it from a drug to a biologic in 2020), not the Controlled Substances Act. The issue is sourcing, not possession.
For competitive athletes: thymosin beta-4 and TB-500 are prohibited at all times under the 2026 WADA Prohibited List (effective January 1, 2026), listed under Section S2 as a growth factor modulator. VADA mirrors this prohibition. Any athlete subject to testing should treat TB-500 as a banned substance regardless of the US compounding ruling.
How do you know TB-500 is actually working? A week-by-week timeline
The most common complaint from first-time users: "Two weeks in and I feel nothing." That response is almost always premature. Here is what the data-backed and community-reported timeline looks like.
| Timeframe | What to expect |
|---|---|
| Weeks 1-2 | Usually no noticeable change. Systemic tissue saturation is building. Subtle anti-inflammatory effects may begin, occasionally noticed as reduced nighttime aching. |
| Weeks 2-4 | First reports of reduced resting ache, slightly improved range of motion, and better sleep quality in the injured area. Still modest. |
| Weeks 4-6 | Most users report the clearest functional improvement in this window: better load tolerance under activity, reduced pain during use, improved joint mobility. This is the primary response window. |
| Weeks 6-10 | Tissue remodeling continues during the maintenance phase and the off-cycle period. Collagen maturation finalizes here. Stopping at week 6 and skipping maintenance cuts this window short. |
No response by week 6 typically means one of two things. First, the injury involves primarily cartilage or bone, where TB-500's human evidence is weakest. Second, you may carry genetic variants that extend the response window: COL5A1 and NOS3 variants are the two strongest predictors of slower-than-average response. Extending the loading phase to 8 weeks before concluding the protocol is not working is a more rational step than stopping early.
The approximate range in tendon injury susceptibility between high-risk and low-risk COL5A1 genotypes in published athlete cohorts. The same variant predicts TB-500 response speed. Slow natural healers often take longer to respond but can reach the same endpoint on an extended loading phase.
How your connective tissue genes change the right TB-500 protocol
TB-500 targets actin sequestration and collagen remodeling. The genes that govern both processes vary between people, and they predict your likely response window more reliably than injury type alone.
COL5A1 encodes Type V collagen, which regulates Type I collagen fibril diameter in tendons and ligaments. The BstUI RFLP variant (CC genotype) is associated with significantly higher injury susceptibility and slower tendon repair in athletes. If your genetic report shows this variant, plan for a 6-week minimum loading phase. Your goal is the same outcome on a longer timeline.
NOS3 (Glu298Asp) affects nitric oxide production. TB-500 signals partly through nitric oxide pathways for vascular healing. Carriers of the T allele produce less endothelial nitric oxide, which blunts the vascular remodeling component. This group benefits more from combining TB-500 with BPC-157, because BPC-157 activates eNOS more aggressively and compensates for the NOS3 shortfall. The Wolverine Stack review covers exactly this combination.
MMP3 5A/5A genotype increases matrix metalloproteinase-3 activity, which accelerates extracellular matrix turnover. Faster matrix turnover may produce a quicker initial response on the loading phase, but also means tissue levels drop faster post-cycle, making the maintenance phase more important for this genotype than for slower remodelers.
Your DNA report from PeptidesDNA includes all three of these variants and ranks connective tissue peptides by your specific response profile. If you want to know whether thymosin beta-4 (TB-500) belongs at the top of your injury protocol, that is the place to start before committing to a 10-week cycle.
The verdict: TB-500 is one of the most pharmacologically coherent injury-repair peptides in use, with a confirmed mechanism, validated human pharmacokinetics, and a Phase 3 controlled human trial showing strong tissue-repair outcomes (in cornea, not tendons, but the mechanism is the same). The standard loading protocol is empirically reasonable even without a musculoskeletal RCT behind it. Run the full 6-week loading phase, do not skip maintenance, and inject in the abdomen since injection site does not change the outcome. If you have not checked your COL5A1 or NOS3 status, a DNA kit or genetic upload will tell you whether to extend your loading phase or pair TB-500 with BPC-157 for the best return on a long protocol cycle.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
How much TB-500 should I take per week?
The standard loading dose is 2.0 to 2.5mg twice weekly (4 to 5mg per week total) for 4 to 6 weeks. Maintenance is 1.5 to 2.0mg once weekly. If dosing by body weight, use 25 mcg/kg per dose as a loading reference: that translates to 2mg for an 80kg person. This aligns with the upper dose range in the only published human pharmacokinetics trial (Wang et al., Journal of Cellular and Molecular Medicine, 2021).
Do you need to inject TB-500 at the injury site?
No. TB-500 distributes systemically after subcutaneous injection, regardless of injection location. The abdomen is the standard site for convenience. Injecting near the injury does not meaningfully increase local tissue concentration compared to a standard subcutaneous site. This is different from BPC-157, which does benefit from local injection near the target tissue. If you are using both peptides, inject TB-500 in the abdomen and BPC-157 near the injury.
How long does a TB-500 cycle typically last?
A complete cycle is loading phase (4-6 weeks) plus maintenance phase (4-8 weeks), totaling 8 to 14 weeks. Most users stop after the loading phase. Effects begin fading within 4 to 8 weeks post-loading if maintenance is skipped, because tissue levels drop below the threshold needed to sustain collagen remodeling. The loading phase builds the result. Maintenance preserves it.
Can you take TB-500 without BPC-157?
Yes. TB-500 is effective as a standalone protocol, particularly for systemic connective tissue repair, chronic tendinopathy, and post-surgical recovery. Stacking with BPC-157 makes sense if you have a specific localized injury (BPC-157 targets it locally while TB-500 works systemically), or if you carry NOS3 variants that reduce TB-500's vascular remodeling response.
What is the difference between TB-500 loading and maintenance dose?
Loading builds systemic tissue saturation quickly using a higher dose at twice-weekly frequency. Maintenance sustains those tissue levels at a lower cost using a reduced dose once weekly. Loading fills the tank. Maintenance prevents it from draining. Both phases are required for the complete protocol effect. Maintenance is the step most users skip, and its absence is the most common reason that initial gains reverse within weeks of stopping.
Is TB-500 legal to buy in the US in 2026?
The regulatory situation is actively evolving. The FDA removed TB-500 from its 503A Category 2 list in April 2026 and scheduled a Pharmacy Compounding Advisory Committee review for July 23-24, 2026. The meeting outcome will determine whether licensed US compounding pharmacies can resume producing it. TB-500 is not a DEA controlled substance. Athletes should note that WADA banned it effective January 1, 2026 under the S2 prohibited list.
How long does TB-500 take to work?
Most users notice the first meaningful effects (reduced resting ache, improved range of motion) between weeks 2 and 4. The clearest functional improvements typically appear between weeks 4 and 6. The full collagen remodeling cycle takes 6 to 10 weeks. If there is no response by week 6, consider extending the loading phase to 8 weeks or checking your COL5A1 and NOS3 genetic status, which are the two strongest predictors of response speed in connective tissue repair.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.